Last week, Lilly reported that Zepbound sales came in at $1.26 billion in the third quarter, roughly $500 million shy of analyst expectations, although, the company said its weekly prescription ...

Novo's drugs Ozempic and Wegovy are household names already, and Lilly's Mounjaro and Zepbound are close behind. For the first nine months of 2024, Novo had sales of $29.4 billion, 23% higher than ...

Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight loss that's sold under the names Mounjaro and Zepbound -- is selling a bit slower than anticipated. Though its ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

Tirzepatide is the active ingredient in Mounjaro and Zepbound. Like Ozempic, Mounjaro is FDA-approved as a diabetes drug. It can help folks with type 2 diabetes control blood sugar levels.

FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also used for weight loss, told CBS News: "Lilly has taken steps to help inform people about ...

The guidelines now recommend that doctors consider prescribing these drugs, including those sold under the brand names Ozempic, Wegovy, Mounjaro and Zepbound, to people with obesity or diabetes.

Last month, the FDA said the shortage of tirzepatide, sold by Eli Lilly as Mounjaro for diabetes and Zepbound for obesity, had been resolved, which was expected to lead to the end of mass ...